BioSpace News Archive

Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB, announced that the US Food and Drug Administration has granted Fast Track designation to emapalumab-lzsg being investigated as a potential therapeutic option in patients with Macrophage Activation Syndrome.

In the intricate landscape of cancer therapeutics, the spotlight has shifted towards reducing the risk of cancer death, unveiling novel opportunities for precision interventions.

Monopar Therapeutics Inc., a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients, announced that after a career spanning more than 35 years, Monopar’s Chief Financial Officer, Kim R. Tsuchimoto, will be retiring.

Astria Therapeutics, Inc., a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, announced that it will present final STAR-0215 Phase 1a healthy subject data in an encore presentation at the upcoming Eastern Allergy Conference in Palm Beach, Florida on June 1, 2024.

Agendia®, Inc., announced that new data on its comprehensive genomic tests will be presented at the American Society of Clinical Oncology Annual Meeting, taking place May 31st – June 4th, 2024, in Chicago, Illinois.

Stereotaxis, a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, announced that it has received CE Mark recertification under the European Union’s new Medical Device Regulation regulatory framework.

Renovaro Inc. and the Amsterdam UMC Cancer Center announced an intended partnership and therefore signed an MoU to establish a joint company based in the Netherlands aimed at pioneering the next generation of personalized cancer immunotherapy.

Eli Lilly and Company announced that it has more than doubled its investment in its Lebanon, Indiana, manufacturing site with a new $5.3 billion commitment, increasing the company’s total investment in this site from $3.7 billion to $9 billion.

Apellis Pharmaceuticals, Inc. and Sobi® announced positive one-year results from the Phase 2 NOBLE study investigating systemic pegcetacoplan, a targeted C3 therapy, for the treatment of post-transplant recurrence of C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis.

G-protein coupled receptor family C group 5 member D, or GPRC5D, has come up as a protein being considered for the development of therapeutic interventions in cancer